Sugi Predict

Sugi Predict / Compounds / SCHEMBL4084246

SCHEMBL4084246

SCHEMBL4084246

O=c1[nH]c2nc(NC3C4COCC3CN(Cc3ccccc3)C4)ncc2cc1-c1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ SIK2 Q9H0K1 2/20 0.39
▸ USP30 Q70CQ3 1/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ TNK2 Q07912 2/20 0.35
▸ FGFR1 P11362 2/20 0.35
▸ PAK1 Q13153 2/20 0.34
▸ PAK2 Q13177 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD4 P21917 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ PDE9A O76083 2/20 0.34
▸ PDE1C Q14123 1/20 0.34
▸ SIK1 P57059 1/20 0.33
▸ SIK3 Q9Y2K2 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ S1PR5 Q9H228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084679 0.89 SIK2 (0.41) LCKMAPK14SIK2USP30ABL1
SCHEMBL4090848 0.83 MAPK14 (0.63) LCKMAPK14ABL1FGFR1FGFR2
SCHEMBL4090690 0.82 LCK (0.51) LCKMAPK14SIK2ABL1TNK2
SCHEMBL13850442 0.80 MAPK14 (0.43) LCKMAPK14SIK2ABL1TNK2
SCHEMBL4090415 0.79 MAPK14 (0.46) LCKMAPK14SIK2ABL1TNK2
SCHEMBL4084813 0.79 ROCK2 (0.48) LCKMAPK14SIK2FGFR1
SCHEMBL4094179 0.77 SIK2 (0.42) LCKMAPK14SIK2ABL1TNK2
SCHEMBL4090637 0.77 SIK2 (0.45) LCKMAPK14SIK2ABL1TNK2
SCHEMBL4094294 0.77 MAPK14 (0.64) LCKMAPK14ABL1FGFR1PAK1
SCHEMBL4096767 0.73 MAPK14 (0.46) LCKMAPK14SIK2ABL1TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 LCK 568/4885MAPK14 3185/4885SIK2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.